Amneal expects to hire an estimated 250-300 employees at the former Johnson & Johnson plant, which was sold by owner Solidus Private Equity, a Singapore-based investment firm.
The Cashel site will be dedicated to R&D and production of metered dose and dry powder inhalers as well as biosimilars.
“Our new Ireland facility is critical to Amneal’s long-term global growth, in Europe, the US and throughout the world,” said Chintu Patel, Amneal Co-CEO and Co-Chairman.